drugset
drugset / Trial / NCT04315246

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

NCT04315246 ↗

Phase 1/2 Withdrawn Y-mAbs Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.

Timeline

Start
2022-08-31
Primary completion
2024-12-31
Completion
2024-12-31

Outcome

Outcome not reported

Stopped (Business): “Business priorities”

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-DTPA-omburtamab Monoclonal antibody — Intrathecal

Indications

neoplastic meningitis